GNCA Average Annual Return Since 2014
Growth of $10,000.00
Without Dividends Reinvested Into GNCA


Also see:
GNCA stock yearly return 2015
GNCA stock yearly return 2016
GNCA stock yearly return 2017
GNCA stock yearly return 2018
GNCA stock yearly return 2019
GNCA stock yearly return 2020
GNCA stock yearly return 2021
GNCA YTD return
Compare GNCA average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 02/06/2014
End date: 06/02/2022
Start price/share: $88.00
End price/share: $0.05
Dividends collected/share: $0.00
Total return: -99.94%
GNCA Average Annual Return: -59.17%
Starting investment: $10,000.00
Ending investment: $5.80
Years: 8.32


GNCA average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS™ platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The GNCA average annual return since 2014 is shown above.

The Average Annual Return on the GNCA average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether GNCA average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the GNCA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree GNCA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Genocea Biosciences (GNCA) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

GNPX Average Annual Return
GOSS Average Annual Return
GOVX Average Annual Return
GRAY Average Annual Return
GRPH Average Annual Return
GRTS Average Annual Return
GRTX Average Annual Return
GTBP Average Annual Return
GTHX Average Annual Return
HAE Average Annual Return
More Healthcare companies »

 

GNCA Average Annual Return Since 2014 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.